AstraZeneca - BRIEF-AstraZeneca Says Symbicort Approved In China For Mild Asthma

AstraZeneca – BRIEF-AstraZeneca Says Symbicort Approved In China For Mild Asthma

* ASTRAZENECA PLC – SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA

* ASTRAZENECA – SYMBICORT TURBUHALER BECOMES FIRST DUAL-COMBINATION THERAPY APPROVED IN CHINA FOR MILD, MODERATE AND SEVERE ASTHMA Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

AstraZeneca – BRIEF-AstraZeneca Says Symbicort Approved In China For Mild Asthma

NYSE:DOW – Dow and The Nature Conservancy celebrate 10 years of groundbreaking collaboration to value nature in business strategy

Visa – Payment Security Market Outlook, Industry Demand and Supply, Key Prospects, Pricing Strategies, Forecast and Top Manufacturers Analysis

Judie Simms

Related Posts

AstraZeneca News – AstraZeneca approval opens door to some B.C. front-line workers getting earlier vaccine

AstraZeneca News – AstraZeneca has sold its stake in Moderna for more than $1 billion: The Times

AstraZeneca News – CoronaVac rollout begins; AstraZeneca delayed

AstraZeneca News – COVID Victoria updates: Vaccine rollout ramps up as AstraZeneca doses land

AstraZeneca News – AstraZeneca to Market Junshi Bio’s PD-1 Cancer Drug in China

AstraZeneca News – German states call for unused AstraZeneca Covid-19 vaccine to be given to younger people, Europe News & Top Stories

AstraZeneca News – Philippines says AstraZeneca vaccine delivery is postponed

AstraZeneca News – AstraZeneca vaccine arrives in Australia

AstraZeneca News – NSW government prepared to step in to help with mass vaccine rollout

Visa - Payment Security Market Outlook, Industry Demand and Supply, Key Prospects, Pricing Strategies, Forecast and Top Manufacturers Analysis

Luxury LifeStyle - Faena Group and Accor embark on global venture to expand the Faena brand worldwide

Leave a Reply Cancel reply